Bollard Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Bollard Group’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-112,400	Closed	-$1.78M	–	380
2022 Q1	$1.78M	Buy	+112,400	New	+$1.94M	0.06%	118

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bollard Group's RCKT Position: Q2 2022 in Review

Bollard Group sold out of Rocket Pharmaceuticals (RCKT) in Q2 2022, closing a stake of 112,400 shares — an estimated $1.78M sold.

Bollard Group first reported a position in RCKT in Q1 2022 and held it in 1 quarter. The position peaked at $1.78M in Q1 2022. 147 funds tracked by Wall St. Rank hold RCKT as of Q2 2022.

Bollard Group reported no remaining Rocket Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bollard Group sold 112,400 Rocket Pharmaceuticals shares in Q2 2022, an estimated $1.78M.
Bollard Group first reported a position in Rocket Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Bollard Group's Rocket Pharmaceuticals position peaked at $1.78M in Q1 2022.
147 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2022.

Based on Bollard Group's 13F filing for Q2 2022, filed 12 Aug 2022.